|
KMID : 1022820190100020027
|
|
Journal of Multiple Sclerosis and Neuroimmunology
2019 Volume.10 No. 2 p.27 ~ p.31
|
|
|
What’s New in Multiple Sclerosis: 2018-2019
|
|
Park Kee-Hong
|
|
|
Abstract
|
|
|
|
Multiple sclerosis (MS) is a demyelinating and inflammatory disease of the central nervous system. Most patients develop MS in the form of relapsing-remitting multiple sclerosis (RRMS). Patients with RRMS also develop neurological deficits over time and progress to secondary progressive MS. A mi- nority of patients develop primary progressive MS, which shows a progressive clinical course from the initial phase of the disease. Development of disease modifying therapies has been focused on RRMS and treatment for progressive MS (secondary progressive multiple sclerosis and primary pro- gressive multiple sclerosis) has been limited. There have been many advances in progressive MS treatment in recent years. This review summarizes recent therapeutic research and explores the neurofilament light chain, which is drawing attention as a biomarker.
|
|
|
KEYWORD
|
|
|
Multiple sclerosis, Demyelinating diseases, Neurofilament proteins
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|